Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis

S. Casati, P. Passerini, M. R. Campise, G. Graziani, B. Cesana, M. Perisic, C. Ponticelli

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

Fourteen patients with uraemic anaemia and having regular haemodialysis were given human recombinant erythopoietin in increasing doses, beginning with 24 U/kg thrice weekly. One patient was dropped from the study because of recurrent thrombosis of vascular access sites. In the other 13 patients, followed up for a mean of 9.1 months (range 8-11), haemoglobin concentrations increased from 62 (SD 8) to 105 (9) g/l. No antierythropoietin antibodies were detected during the study. The correction of anaemia was associated with a tendency to hyperkalaemia and a mild increase of unconjugated bilirubinaemia. In eight previously hypertensive patients antihypertensive treatment had to be reinforced, but in normotensive patients blood pressure did not change. Thrombosis of arteriovenous fistulas occurred in two patients and a cerebral ischaemic lesion in one. Protracted treatment with human recombinant erythropoietin evidently can maintain normal haemoglobin concentrations in uraemic patients over time. Full correction of anaemia, however, may trigger some vascular problems, particularly in hypertensive patients and those with a tendency to thromboembolism.

Original languageEnglish
Pages (from-to)1017-1020
Number of pages4
JournalBritish Medical Journal
Volume295
Issue number6605
Publication statusPublished - 1987

Fingerprint

Erythropoietin
Renal Dialysis
Anemia
Therapeutics
Blood Vessels
Hemoglobins
Thrombosis
Hyperkalemia
Hyperbilirubinemia
Thromboembolism
Arteriovenous Fistula
Antihypertensive Agents
Blood Pressure
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Casati, S., Passerini, P., Campise, M. R., Graziani, G., Cesana, B., Perisic, M., & Ponticelli, C. (1987). Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. British Medical Journal, 295(6605), 1017-1020.

Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. / Casati, S.; Passerini, P.; Campise, M. R.; Graziani, G.; Cesana, B.; Perisic, M.; Ponticelli, C.

In: British Medical Journal, Vol. 295, No. 6605, 1987, p. 1017-1020.

Research output: Contribution to journalArticle

Casati, S, Passerini, P, Campise, MR, Graziani, G, Cesana, B, Perisic, M & Ponticelli, C 1987, 'Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis', British Medical Journal, vol. 295, no. 6605, pp. 1017-1020.
Casati, S. ; Passerini, P. ; Campise, M. R. ; Graziani, G. ; Cesana, B. ; Perisic, M. ; Ponticelli, C. / Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. In: British Medical Journal. 1987 ; Vol. 295, No. 6605. pp. 1017-1020.
@article{2c1af998fa59446e98856ee4b390f602,
title = "Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis",
abstract = "Fourteen patients with uraemic anaemia and having regular haemodialysis were given human recombinant erythopoietin in increasing doses, beginning with 24 U/kg thrice weekly. One patient was dropped from the study because of recurrent thrombosis of vascular access sites. In the other 13 patients, followed up for a mean of 9.1 months (range 8-11), haemoglobin concentrations increased from 62 (SD 8) to 105 (9) g/l. No antierythropoietin antibodies were detected during the study. The correction of anaemia was associated with a tendency to hyperkalaemia and a mild increase of unconjugated bilirubinaemia. In eight previously hypertensive patients antihypertensive treatment had to be reinforced, but in normotensive patients blood pressure did not change. Thrombosis of arteriovenous fistulas occurred in two patients and a cerebral ischaemic lesion in one. Protracted treatment with human recombinant erythropoietin evidently can maintain normal haemoglobin concentrations in uraemic patients over time. Full correction of anaemia, however, may trigger some vascular problems, particularly in hypertensive patients and those with a tendency to thromboembolism.",
author = "S. Casati and P. Passerini and Campise, {M. R.} and G. Graziani and B. Cesana and M. Perisic and C. Ponticelli",
year = "1987",
language = "English",
volume = "295",
pages = "1017--1020",
journal = "British Medical Journal",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "6605",

}

TY - JOUR

T1 - Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis

AU - Casati, S.

AU - Passerini, P.

AU - Campise, M. R.

AU - Graziani, G.

AU - Cesana, B.

AU - Perisic, M.

AU - Ponticelli, C.

PY - 1987

Y1 - 1987

N2 - Fourteen patients with uraemic anaemia and having regular haemodialysis were given human recombinant erythopoietin in increasing doses, beginning with 24 U/kg thrice weekly. One patient was dropped from the study because of recurrent thrombosis of vascular access sites. In the other 13 patients, followed up for a mean of 9.1 months (range 8-11), haemoglobin concentrations increased from 62 (SD 8) to 105 (9) g/l. No antierythropoietin antibodies were detected during the study. The correction of anaemia was associated with a tendency to hyperkalaemia and a mild increase of unconjugated bilirubinaemia. In eight previously hypertensive patients antihypertensive treatment had to be reinforced, but in normotensive patients blood pressure did not change. Thrombosis of arteriovenous fistulas occurred in two patients and a cerebral ischaemic lesion in one. Protracted treatment with human recombinant erythropoietin evidently can maintain normal haemoglobin concentrations in uraemic patients over time. Full correction of anaemia, however, may trigger some vascular problems, particularly in hypertensive patients and those with a tendency to thromboembolism.

AB - Fourteen patients with uraemic anaemia and having regular haemodialysis were given human recombinant erythopoietin in increasing doses, beginning with 24 U/kg thrice weekly. One patient was dropped from the study because of recurrent thrombosis of vascular access sites. In the other 13 patients, followed up for a mean of 9.1 months (range 8-11), haemoglobin concentrations increased from 62 (SD 8) to 105 (9) g/l. No antierythropoietin antibodies were detected during the study. The correction of anaemia was associated with a tendency to hyperkalaemia and a mild increase of unconjugated bilirubinaemia. In eight previously hypertensive patients antihypertensive treatment had to be reinforced, but in normotensive patients blood pressure did not change. Thrombosis of arteriovenous fistulas occurred in two patients and a cerebral ischaemic lesion in one. Protracted treatment with human recombinant erythropoietin evidently can maintain normal haemoglobin concentrations in uraemic patients over time. Full correction of anaemia, however, may trigger some vascular problems, particularly in hypertensive patients and those with a tendency to thromboembolism.

UR - http://www.scopus.com/inward/record.url?scp=0023640448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023640448&partnerID=8YFLogxK

M3 - Article

C2 - 3120854

AN - SCOPUS:0023640448

VL - 295

SP - 1017

EP - 1020

JO - British Medical Journal

JF - British Medical Journal

SN - 0959-8146

IS - 6605

ER -